AC Immune to Present New Data Demonstrating the Depth of its Neurodegenerative Programs at the Upcoming Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting
The four presentations will focus on advances in wholly-owned as well as partnered product programs. One presentation will showcase nonclinical data involved in the development of the anti-phospho Tau (anti-pTau) vaccine, ACI-35.030, currently in Phase 2 clinical testing. Two presentations will highlight our work to target TDP-43 proteinopathies including the mitigation of associated neuropathology using our therapeutic antibody candidate in an animal model of human disease and our efforts to develop the first in class candidate for molecular imaging of TDP-43 in humans. The final presentation will describe the discovery and characterization of an antibody that targets the spreading of alpha-synuclein in vitro and in vivo.
Prof.
Scientific updates at the AAT-AD/PD™ Focus Meeting 2020,
ACI-35.030 anti-pTau vaccine
Development of ACI-35.030, a second generation anti-phospho Tau vaccine, in clinical evaluation for the treatment of Alzheimer’s disease
Date: April 2, 2020 | 6:15 – 6:35 pm CET
Location: Hall E
Presenter: Oral presentation by
Morphomer™ TDP-43 imaging
Discovery and optimization of candidates for molecular imaging of TDP-43 proteinopathies
Date: April 3, 2020 | 9:41 –
Location: Hall M
Presenter: Short oral poster presentation by
Anti-TDP-43 antibody
Monoclonal antibody targeting TDP-43 mitigates associated neuropathology in mouse model of TDP-43 proteinopathy
Date: April 3, 2020 | 3:30 –
Location: Hall F1
Presenter: Oral presentation by
Anti-alpha-synuclein antibody
Targeting spreading of pathological alpha-synuclein to treat Parkinson’s disease
Date: April 5, 2020 | 9:15 – 9:35 am CET
Location: Hall M
Presenter: Oral presentation by
About
For further information, please contact:
Head of Investor Relations Phone: +1 917 809 0814 Email: joshua.drumm@acimmune.com |
US Media LaVoieHealthScience Phone: +1 617 792 3937 Email: kgallagher@lavoiehealthscience.com |
Global Head of Communications Phone: +41 79 826 63 82 Email: judith.moore@acimmune.com |
Phone: +41 79 367 6254 Email: chris@lifesciadvisors.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Source: AC Immune SA